Suppr超能文献

越南谅山省使用的孕早期子痫前期筛查算法比较

Comparison of Pre-eclampsia Screening Algorithms in the First Trimester of Pregnancy Being Used in Thai Nguyen Province.

作者信息

Huong Luong T, Lan Le Thi H, Hong Ha Thi V, Cuong Nguyen V

机构信息

Obstetrics and Gynaecology, Thai Nguyen National Hospital, Thai Nguyen, VNM.

Biochemistry, Thai Nguyen National Hospital, Thai Nguyen, VNM.

出版信息

Cureus. 2024 Apr 27;16(4):e59133. doi: 10.7759/cureus.59133. eCollection 2024 Apr.

Abstract

Objective To compare the rates of pregnancies in high-risk groups for preeclampsia recommended for aspirin prophylactic when screened using various common algorithms. Methods This cross-sectional study was conducted on 1726 pregnant women from 11 to 13 weeks six days of gestation receiving antenatal care at two hospitals: Thai Nguyen National Hospital and a hospital in Thai Nguyen Province from October 2022 to October 2023. All participants provided consent for the study. We collected maternal characteristics, obstetric history, mean arterial pressure (MAP), mean uterine artery-PI (UtA-PI), and placental growth factor serum (PLGF). Screening performance estimates were calculated using the Fetal Medicine Foundation (FMF) and National Institute for Health and Care Excellence (NICE) guidelines. All pregnant women in the study had their preeclampsia risk assessed using all three algorithms with two cut-off points. Our data was collected, entered and analyzed using SPSS software 20.0 (IBM Corp., Armonk, NY). Categorical data was reported as frequency and percentage. McNemar's test was used for analyzing differences in the sizes of individual groups. Results In our study, the most common high-risk factor identified was the history of preeclampsia, 132 cases (7.6%). According to the NICE guideline, BMI ≥ 35 (kg/m²) is considered a moderate risk factor for preeclampsia. Several risk factors, such as BMI ≥ 35 kg/m² and history of diabetes mellitus type 1, were not present in any participants. Only one pregnant woman had chronic kidney disease (0.06%). Out of the 1726 pregnant women surveyed, the rates of high-risk preeclampsia were as follows: 9.9% (171 cases) based on algorithm 1; 10.8% (187 cases) based on algorithm 2 with a cut-off point > 1/100, 11.8% (203 cases) with a cut-off point > 1/150; 10.3 % (178 cases) based on algorithm 3 with a cut-off point > 1/100, and 11.6% (201 cases) with a cut-off point > 1/150. Among these algorithms, pregnant women in the high-risk preeclampsia group were advised to consider taking low-dose aspirin. Conclusion Screening for pre-eclampsia based on NICE recommendations resulted in a lower number of high-risk pregnant women requiring prophylactic aspirin use compared to other algorithms. This means that some pregnant women at risk of developing preeclampsia are not recommended to use aspirin as a preventive measure. Adding PLGF to the screening strategy will help us get closer to pregnant women who are truly at risk of progressing to preterm preeclampsia.

摘要

目的 比较使用各种常见算法进行筛查时,子痫前期高危组中推荐使用阿司匹林进行预防的妊娠率。方法 本横断面研究于2022年10月至2023年10月在两家医院对1726例妊娠11至13⁺⁶周接受产前检查的孕妇进行:太原国立医院和太原省的一家医院。所有参与者均同意参与本研究。我们收集了产妇特征、产科病史、平均动脉压(MAP)、平均子宫动脉搏动指数(UtA-PI)和胎盘生长因子血清(PLGF)。使用胎儿医学基金会(FMF)和英国国家卫生与临床优化研究所(NICE)指南计算筛查性能估计值。本研究中的所有孕妇均使用三种算法及两个截断点评估子痫前期风险。我们的数据使用SPSS软件20.0(IBM公司,纽约州阿蒙克)进行收集、录入和分析。分类数据以频率和百分比形式报告。使用McNemar检验分析各个组大小的差异。结果 在我们的研究中,确定的最常见高危因素是子痫前期病史,132例(7.6%)。根据NICE指南,BMI≥35(kg/m²)被认为是子痫前期的中度危险因素。一些危险因素,如BMI≥35 kg/m²和1型糖尿病病史,在任何参与者中均未出现。只有一名孕妇患有慢性肾脏病(0.06%)。在接受调查的1726例孕妇中,子痫前期高危率如下:基于算法1为9.9%(171例);基于算法2,截断点>1/100时为10.8%(187例),截断点>1/150时为11.8%(203例);基于算法3,截断点>1/100时为10.3%(178例),截断点>1/150时为11.6%(201例)。在这些算法中,子痫前期高危组的孕妇被建议考虑服用低剂量阿司匹林。结论 与其他算法相比,基于NICE建议进行子痫前期筛查导致需要预防性使用阿司匹林的高危孕妇数量较少。这意味着一些有子痫前期发病风险的孕妇不建议使用阿司匹林作为预防措施。在筛查策略中加入PLGF将有助于我们更接近真正有进展为早发型子痫前期风险的孕妇。

相似文献

1
Comparison of Pre-eclampsia Screening Algorithms in the First Trimester of Pregnancy Being Used in Thai Nguyen Province.
Cureus. 2024 Apr 27;16(4):e59133. doi: 10.7759/cureus.59133. eCollection 2024 Apr.
2
Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
Am J Obstet Gynecol. 2019 Dec;221(6):650.e1-650.e16. doi: 10.1016/j.ajog.2019.09.041. Epub 2019 Oct 4.
3
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Ultrasound Obstet Gynecol. 2020 Sep;56(3):400-407. doi: 10.1002/uog.22093. Epub 2020 Aug 5.
4
First trimester preeclampsia screening and prediction.
Am J Obstet Gynecol. 2022 Feb;226(2S):S1071-S1097.e2. doi: 10.1016/j.ajog.2020.07.020. Epub 2020 Jul 16.
5
Pre-eclampsia screening in Denmark (PRESIDE): national validation study.
Ultrasound Obstet Gynecol. 2023 Jun;61(6):682-690. doi: 10.1002/uog.26183. Epub 2023 May 5.
6
ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
Ultrasound Obstet Gynecol. 2021 Oct;58(4):546-552. doi: 10.1002/uog.23668. Epub 2021 Sep 6.
7
Accuracy of second trimester prediction of preterm preeclampsia by three different screening algorithms.
Aust N Z J Obstet Gynaecol. 2018 Apr;58(2):192-196. doi: 10.1111/ajo.12689. Epub 2017 Aug 29.
9
Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening.
PLoS One. 2023 Jul 10;18(7):e0288289. doi: 10.1371/journal.pone.0288289. eCollection 2023.

引用本文的文献

本文引用的文献

1
First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study.
BJOG. 2024 Jan;131(2):222-230. doi: 10.1111/1471-0528.17598. Epub 2023 Jul 11.
2
Preeclampsia Incidence and Its Maternal and Neonatal Outcomes With Associated Risk Factors.
Cureus. 2022 Nov 6;14(11):e31143. doi: 10.7759/cureus.31143. eCollection 2022 Nov.
3
Effectiveness of Different Algorithms and Cut-off Value in Preeclampsia First Trimester Screening.
J Pregnancy. 2022 Apr 8;2022:6414857. doi: 10.1155/2022/6414857. eCollection 2022.
4
Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China.
JAMA Netw Open. 2021 May 3;4(5):e218401. doi: 10.1001/jamanetworkopen.2021.8401.
5
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Ultrasound Obstet Gynecol. 2020 Sep;56(3):400-407. doi: 10.1002/uog.22093. Epub 2020 Aug 5.
8
ASPRE trial: performance of screening for preterm pre-eclampsia.
Ultrasound Obstet Gynecol. 2017 Oct;50(4):492-495. doi: 10.1002/uog.18816. Epub 2017 Aug 24.
10
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12. doi: 10.1016/j.ajog.2015.08.034. Epub 2015 Aug 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验